View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 16, 2020updated 12 Jul 2022 11:56am

Vanda Pharmaceuticals starts Phase III Covid-19 trial of tradipitant

Vanda Pharmaceuticals has partnered with The Feinstein Institutes for Medical Research's arm Northwell Health to conduct a Phase III clinical trial of tradipitant to treat severe Covid-19 pneumonia.

Vanda Pharmaceuticals has partnered with The Feinstein Institutes for Medical Research’s arm Northwell Health to conduct a Phase III clinical trial of tradipitant to treat severe Covid-19 pneumonia.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Enrolment for the trial, called ODYSSEY, has begun. The first patient was enrolled on 15 March at Lenox Hill Hospital, New York City, US.

Tradipitant is a neurokinin-1 receptor (NK-1R) antagonist licensed by the company from Eli Lilly. The drug is being developed to treat gastroparesis, motion sickness, and atopic dermatitis.

The double-blind, placebo-controlled, randomised ODYSSEY trial will assess the safety and efficacy of oral, 85mg twice-daily dose of the drug in treating neurogenic inflammation of the lung caused by Covid-19.

SARS-CoV-2, the novel coronavirus that causes Covid-19, is responsible for inflammation of the lower respiratory tract, which may progress to acute respiratory distress syndrome (ARDS) requiring mechanical ventilation.

The Phase III trial is designed to recruit around 300 participants with confirmed Covid-19 pneumonia. Patients will be given tradipitant or placebo.

Clinical and laboratory outcomes will be monitored to establish the tradipitant’s efficacy in treating pneumonia associated with the novel coronavirus infection.

Vanda Pharmaceuticals president and CEO Mihael Polymeropoulos said: “With the strong leadership and health expertise of Northwell Health, we expect to be able to accelerate enrollment in this study and provide results in the coming months.

“As the mortality rate from Covid-19 continues to rise in New York from ARDS, it is critical for clinical research to be fully embraced by the public, scientific community, health professionals and the government.”

The primary outcome of the Phase III trial is the proportion of patients with normalisation of fever and oxygen saturation by day 14.

Secondary outcome measures include inflammatory lung injury, viral load, and in-hospital mortality, among others.

The study is expected to be completed in August this year.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena